DLC1 and breast carcinoma: The idea that aberrant RhoA activation drives breast cancer metastasis fits with the findings of others indicating that reduced expression of the RhoA subfamily-specific GAP DLC-1 is predictive of metastatic spread to the bone in all breast cancer subtypes [18].